MRK

Announcements

Nothing here yet

Daily updates

• Merck reported detailed Phase 2b data for tulisokibart in hidradenitis suppurativa. At the high and medium doses, 72% and 64% of patients, respectively, achieved at least a 50% reduction in abscesses and inflammatory nodules, representing placebo-adjusted advantages of 37% and 29% and supporting late-stage development.Oct 1, 2026
• Merck signed a global licensing agreement for a KRAS G12D inhibitor from China’s SciBrunch Therapeutics, paying $400 million upfront.Sep 30, 2026
• Merck's Ezmekly was cleared for NHS use in children with NF1-associated tumoursSep 7, 2026

FDA designations

• Merck and Daiichi Sankyo’s Raludotatug Deruxtecan Receives FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian and Related CancersSep 15, 2025
• FDA Grants Breakthrough Therapy Designation to Ifinatamab Deruxtecan for Extensive-Stage Small Cell Lung CancerAug 18, 2025

News

• Merck presents pivotal Phase 3 results from its oncology pipeline for the first time and highlights the continued innovative potential of its existing portfolio at ESMO 2026Oct 13, 2026
• Merck presents one-year results from the pivotal Phase 2b/3 BRUNELLO study of remigromig, a trispecific Wnt-pathway agonist, in adults with diabetic macular edema at AAO 2026Oct 11, 2026
• Merck's antibody delivers highly competitive clinical data in a chronic skin diseaseOct 1, 2026
• Merck enters an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitorSep 28, 2026
• Merck voluntarily withdraws the biologics license application for ifinatamab deruxtecan in certain previously treated patients with extensive-stage small cell lung cancerSep 26, 2026